CG Oncology (CGON) Gross Margin (2024 - 2026)

CG Oncology has reported Gross Margin for 3 years, with the latest figure at 173.5% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin fell 27350.0% year-over-year to 173.5%; the trailing twelve-month figure through Mar 2026 stood at 49.02% (changed N/A YoY), and the FY2025 full-year result was 15.02%, down 11502.0% from the prior year.
• Gross Margin for Q1 2026 stood at 173.5%, down from 32.21% in the prior quarter.
• The five-year high for Gross Margin was 100.0% in Q3 2024, with the low at 173.5% in Q1 2026.
• Historically, Gross Margin has averaged 16.6% across 3 years, with a median of 52.67% in 2024.
• Annual changes were most pronounced in 2025 — Gross Margin tumbled 9466 bps — and 2026, when it tumbled 27350 bps.
• CG Oncology's Gross Margin stood at 100.0% in 2024, then slumped by 132 bps to 32.21% in 2025, then plunged by 439 bps to 173.5% in 2026.
• The last three Gross Margin figures came in at 173.5% (Q1 2026), 32.21% (Q4 2025), and 5.34% (Q3 2025), per Business Quant data.